The recent approval of Eli Lilly and Company’s Zepbound (tirzepatide) for obesity means two highly effective incretin drugs are now available for obesity. Lilly believes it can supply Zepbound in large quantities from the off, besting Novo Nordisk A/S which has been unable to make Wegovy (semaglutide 2.4mg injection) in sufficient amounts to meet demand.
Novo has other advantages, notably the chance to get a cardiovascular protection claim on Wegovy’s label on the basis of...